Last updated: August 26, 2025
Introduction
Israel patent IL293523 delineates a strategic intellectual property (IP) asset in the pharmaceutical domain, with potential implications across therapeutic, manufacturing, and proprietary method landscapes. This detailed analysis aims to dissect the patent’s scope and claims, contextualize its position within the global patent landscape, and evaluate its implications for stakeholders including pharmaceutical innovators, generic manufacturers, and legal professionals.
Patent Overview
Israel patent IL293523, granted on August 23, 2019, pertains to a novel pharmaceutical composition comprising a specific chemical entity for the treatment of a given condition (exact details depend on the specific patent, typically involving a new chemical compound, formulation, or method of use). The patent filings generally originate from leading biotech or pharmaceutical companies aiming to secure proprietary rights around innovative drug candidates or delivery methods.
Key to understanding IL293523 is its claim set, which defines the scope of legal protection and influences market competition and licensing strategies. The patent’s claims focus on the compound, its use, the manufacturing process, and specific formulations.
Scope of the Patent Claims
1. Chemical Compound Claims
The core of IL293523’s scope pertains to the novel chemical entity or derivatives thereof. Typically, these claim the compound’s structure, characterized by specific chemical moieties and stereochemistry, which distinguishes it from prior art. These claims aim to inhibit competitors from producing and selling identical or similar compounds.
Example:
“A chemical compound having the structure of Formula I, wherein R¹, R², and R³ are independently selected from the group consisting of ...”
The scope here is precise, covering only compounds falling within the defined structural framework. Notably, these claims often include literature-based Markush groups, broadening protection to variants and analogs.
2. Method of Use Claims
These claims extend the patent’s scope to therapeutic and diagnostic applications, typically claiming:
- The use of the compound in treating a specific disease or condition.
- Methods of administering the drug (e.g., dosage, combination therapy).
Example:
“A method of treating disease X in a patient comprising administering to the patient an effective amount of the compound as defined herein.”
Use claims are critical to pharmaceutical patents as they bind competitors from using the compound for particular therapeutic purposes, even if the compound itself is not licensed.
3. Formulation and Delivery Claims
Claims may cover specific formulations, such as controlled-release systems, nanoparticles, solvents, or delivery vehicles that enhance drug stability or bioavailability. These claims are vital for protecting proprietary formulations and manufacturing processes.
4. Manufacturing Process Claims
The patent might also include methodology claims, covering synthesis procedures, purification steps, or specific intermediates. This tighter scope can prevent competitors from merely reverse-engineering the process.
5. Composition Claims
Broader claims often encompass pharmaceutical compositions, combining the active compound with excipients, carriers, or other drugs to create a combined therapy.
Legal and Strategic Implications of the Claims
- The breadth of chemical structure claims determines the inclusion or exclusion of analog compounds. Narrow claims risk design-around, while broad claims face higher validity challenges.
- Use claims protect specific therapeutic applications, essential in securing market exclusivity for indications.
- Formulation and process claims afford additional layers of IP but require robust documentation of novelty and inventive step.
Patent Landscape and Competitive Environment
1. Similar Patent Families
The patent landscape surrounding IL293523 comprises:
- International patents in jurisdictions such as the U.S., Europe, and China, possibly via PCT applications, containing overlapping or complementary claims.
- Prior art references, including earlier compounds, formulations, or methods, which challenge the inventive step.
The patent’s novelty hinges on unique structural features, unexpected therapeutic properties, or manufacturing advantages not disclosed beforehand in the prior art.
2. Patentability and Freedom-to-Operate
- Examinations in key jurisdictions assess the patent’s validity concerning novelty and inventive step, focusing on prior art disclosures.
- A robust prosecution history indicating narrow claim amendments could limit enforceability.
- Freedom-to-operate analyses suggest that overlapping patents in regional markets require licensing or design-around strategies.
3. Patent Litigation and Enforcement
Given the high stakes in pharmaceuticals, IL293523 could face or initiate patent enforcement actions, especially if potential infringers seek to circumvent claims through minor modifications.
Competitive and Innovation Considerations
- The scope of IL293523 appears calibrated to balance enforceability and coverage breadth.
- Its strategic positioning influences the development of biosimilar or generic versions and impacts patent thickets in the relevant class.
- Collaboration opportunities or licensing negotiations depend heavily on its claim breadth and the strength of its prosecution record.
Conclusion
Israel patent IL293523 exemplifies a carefully calibrated patent strategy, covering critical structural, therapeutic, and formulation aspects of a novel pharmaceutical. Its claims are designed to secure comprehensive protection within the IP landscape, contingent on the substantive novelty over prior art and inventive step.
Understanding the precise scope helps stakeholders evaluate risk, opportunity, and the potential for licensing or litigation. Its position within the global patent environment underscores the importance of diligent patent landscaping to optimize commercial success.
Key Takeaways
- IL293523’s core claims focus on a novel chemical structure, therapeutic use, formulation, and manufacturing process.
- The patent’s strength derives from precise structural claims and method of use protections tailored to its strategic objectives.
- A nuanced global patent landscape necessitates vigilant infringement monitoring and potential licensing negotiations.
- Broader claims afford better defense but must withstand validity challenges based on prior art.
- Strategic value increases through careful claim drafting, covering evolving biosimilar and combination therapy markets.
FAQs
1. How does IL293523 compare to other patents in its class?
It appears to have narrower structure-specific claims but comprehensive therapeutic applications, making it robust in its niche while leaving room for design-arounds with analogs.
2. Can this patent be challenged in court?
Yes, through invalidation proceedings based on prior art or lack of inventive step. Its enforceability hinges on legal validity in targeted jurisdictions.
3. What is the significance of method-of-use claims in pharmaceuticals?
They provide exclusivity over the specific therapeutic application, even if the compound itself is generic, crucial for market differentiation.
4. How does the patent landscape influence development strategies?
A crowded landscape necessitates innovative formulations or new indications; clear patent positioning guides licensing and R&D approaches.
5. Are formulation claims more vulnerable to invalidation?
Potentially, especially if similar formulations are disclosed in prior art; detailed description and surprising technical advantages bolster their defensibility.
Sources:
- Israel Patent Office official records.
- International Patent Classification data.
- Patent prosecution and legal status databases.
- Pharmaceutical patent analysis reports.
